Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

BioDrugs

Issue Special Issue 1/2014

Optimisation of TNF-Inhibitor Therapy for Rheumatoid Arthritis: Focus on Certolizumab Pegol

Content (5 Articles)

Optimisation of TNF-Inhibitor Therapy for Rheumatoid Arthritis: Focus on Certolizumab Pegol

Foreword

How FABulous is PEGgy? Certoliziumab Pegol from the Bench to the Patients

Daniel Aletaha

Review Article

Tumour Necrosis Factor α Antagonists in the Treatment of Rheumatoid Arthritis: An Immunological Perspective

Pier-Luigi Meroni, Guido Valesini

Review Article

Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol

Gianfranco Pasut

Review Article

Efficacy and Safety of Certolizumab Pegol in Rheumatoid Arthritis: Meeting Rheumatologists’ Requirements in Routine Clinical Practice

Leonardo Punzi, Giovanni Lapadula, Alessandro Mathieu

Feb 14
Issue: 1/2014
Apr 14
Issue: 2/2014

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more